Mature messenger RNA

ProfNet Expert Alerts for December 02, 2022

Retrieved on: 
Friday, December 2, 2022
Student, Medicine, Mature messenger RNA, Vaccine, GHG, Greenhouse, Greenhouse gas, Climate, Research, RNA, MD, Reading, University of Massachusetts, STEM, Engineering, Methane, Thought, Agriculture

NEW YORK, Dec. 2, 2022 /PRNewswire/ -- Below are experts from the ProfNet network who are available to discuss timely issues in your coverage area.

Key Points: 
  • Dr. Wang can speak about the research as a principal investigator at UMass Chan and the current state of the flu season.
  • "There are so many ways to teach STEM principles across a variety of subjects and across grade levels.
  • Impact severity of the different types of GHGs - how methane is the only viable solution to save humanity.
  • Solutions for today to reduce GHG while we wait for other technology to catch up.

Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine

Retrieved on: 
Wednesday, September 14, 2022
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Well, Hospital, Mature messenger RNA, YouTube, Phase II, Safety, Trial of the century, Development, COVID-19, Twitter, NYSE, Risk, RNA transfection, Orthornavirae, World Health Organization, U.S. Securities and Exchange Commission, News, Vaccination, LinkedIn, Senior, Inc., Infection, Program, Clinical trial, Facebook, Indigenous, SaRNA, Viral disease, Vaccine, Female, CDC, JAMA Network Open, BioNTech, Science, Black, PFE, RNA, Research, Influenza, Death, Pharmaceutical industry, Medical device, Animal husbandry, Pfizer

We are excited to start the first Phase 3 efficacy study of an mRNA-based influenza vaccine that could potentially deliver an improved flu vaccine to help address the significant burden of this disease.

Key Points: 
  • We are excited to start the first Phase 3 efficacy study of an mRNA-based influenza vaccine that could potentially deliver an improved flu vaccine to help address the significant burden of this disease.
  • This Phase 3 study is informed by previously shared data from the ongoing Phase 2 trial which demonstrates a safety and immunogenicity profile supportive of program advancement and is part of Pfizers broader influenza vaccine program, focused on leveraging mRNA technology in a vaccine to help protect against the flu.
  • In 2018, Pfizer entered into a worldwide collaboration and license agreement with BioNTech under which Pfizer has the exclusive right to carry out the clinical development and commercialization of mRNAbased influenza vaccines.
  • doi:10.1001/jamanetworkopen.2020.37640
    8 Recommended composition of influenza virus vaccines for use in the 2021-2022 northern hemisphere influenza season.